Pelareorep and Paclitaxel Injection in Chinese Patients With Advanced or Metastatic Breast Cancer
- First Posted Date
- 2022-08-29
- Last Posted Date
- 2023-11-22
- Lead Sponsor
- Adlai Nortye Biopharma Co., Ltd.
- Target Recruit Count
- 15
- Registration Number
- NCT05519059
- Locations
- 🇨🇳
Bethune First Hospital of Jilin University, Chang chun, Jilin, China
AN0025 and Chemoradiotherapy Combination in Esophageal Cancer
- First Posted Date
- 2022-01-13
- Last Posted Date
- 2025-02-13
- Lead Sponsor
- Adlai Nortye Biopharma Co., Ltd.
- Target Recruit Count
- 32
- Registration Number
- NCT05191667
- Locations
- 🇨🇳
Jianming Xu, Beijing, Beijing, China
First in Human, Dose Escalation Study of AN4005
- Conditions
- Advanced LymphomaAdvanced Solid Tumor
- Interventions
- Drug: AN4005-dose level 3Drug: AN4005-dose level 0Drug: AN4005-dose level 1Drug: AN4005-dose level 2Drug: AN4005-food effectDrug: AN4005-dose level 4
- First Posted Date
- 2021-08-10
- Last Posted Date
- 2024-10-24
- Lead Sponsor
- Adlai Nortye Biopharma Co., Ltd.
- Target Recruit Count
- 31
- Registration Number
- NCT04999384
- Locations
- 🇺🇸
Next Virginia, Fairfax, Virginia, United States
🇨🇳Beijing Cancer Hospital, Beijing, Beijing, China
🇺🇸Hackensack University Medical Center, Hackensack, New Jersey, United States
Double/Triple Combinations of AN2025, AN0025 and Atezolizumab in Advanced Solid Tumors
- Conditions
- Locally Advanced Solid Tumor
- Interventions
- First Posted Date
- 2021-07-26
- Last Posted Date
- 2024-10-24
- Lead Sponsor
- Adlai Nortye Biopharma Co., Ltd.
- Target Recruit Count
- 63
- Registration Number
- NCT04975958
- Locations
- 🇺🇸
Stephenson Cancer Center, Oklahoma City, Oklahoma, United States
🇺🇸Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
🇺🇸University of Colorado Cancer Center, Aurora, Colorado, United States
AN0025 and Pembrolizumab Combination in Advanced Solid Tumors
- Conditions
- NSCLC, Squamous or Non-SquamousTriple-negative Breast CancerMicrosatellite Stable (MSS) Colorectal Cancer (CRC)Cervical CancerUrothelial Carcinoma of the Bladder
- Interventions
- First Posted Date
- 2020-06-16
- Last Posted Date
- 2024-06-27
- Lead Sponsor
- Adlai Nortye Biopharma Co., Ltd.
- Target Recruit Count
- 63
- Registration Number
- NCT04432857
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸University of Virginia, Richmond, Virginia, United States
🇫🇷Centre Léon Bérard, Lyon, France
The BURAN Study of Buparlisib in Patients With Recurrent or Metastatic HNSCC
- Conditions
- Head and Neck Cancer
- Interventions
- First Posted Date
- 2020-04-08
- Last Posted Date
- 2025-02-14
- Lead Sponsor
- Adlai Nortye Biopharma Co., Ltd.
- Target Recruit Count
- 483
- Registration Number
- NCT04338399
- Locations
- 🇺🇸
UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States
🇺🇸Northwestern University, Chicago, Illinois, United States
🇺🇸University of Cincinnati Cancer Center, Cincinnati, Ohio, United States
Preoperative Radiotherapy and E7046 in Rectum Cancer
- Conditions
- Neoadjuvant Therapy in Rectal Cancer
- Interventions
- Radiation: Long Course Chemoradiotherapy (LCRT)Radiation: Short Course Radiotherapy (SCRT)Drug: folinic acid/5-FU/oxaliplatin (mFOLFOX-6)
- First Posted Date
- 2017-05-15
- Last Posted Date
- 2021-10-04
- Lead Sponsor
- Adlai Nortye Biopharma Co., Ltd.
- Target Recruit Count
- 29
- Registration Number
- NCT03152370
- Locations
- 🇬🇧
The Christie, Manchester, United Kingdom
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Weill Cornell, New York, New York, United States